SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001628280-23-030697
Filing Date
2023-08-28
Accepted
2023-08-28 08:55:55
Documents
115
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A akba-20221231.htm   iXBRL 10-K/A 3084961
2 EX-23.1 exhibit231-eyakebiaconsent.htm EX-23.1 9497
3 EX-31.1 akbaex31112312022-10xka.htm EX-31.1 10900
4 EX-31.2 akbaex31212312022-10xka.htm EX-31.2 10960
5 EX-32.1 akbaex32112312022-10xka.htm EX-32.1 8245
  Complete submission text file 0001628280-23-030697.txt   15862390

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20221231.xsd EX-101.SCH 122006
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT akba-20221231_cal.xml EX-101.CAL 115790
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20221231_def.xml EX-101.DEF 594383
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20221231_lab.xml EX-101.LAB 1191151
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20221231_pre.xml EX-101.PRE 857436
109 EXTRACTED XBRL INSTANCE DOCUMENT akba-20221231_htm.xml XML 2836119
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36352 | Film No.: 231210523
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences